RE:RE:RE:Skinmedica Dark spot remover turnover let's have a little guess
-R&F
50k upfront
6kg 8.000 USD = 48k
-Allergan
500k upfront
250k milestones
2m in annual sales would mean 100k in revenue at 5% royalties (x 17 years = 1,7m)
-total value
=2.548k
Is that realistic for a Dark Spot remover? after all, it is only an add on
Not exactly what they told us investors but at least a little turnover. there will be no profitable venture with tfc 1067. Probably no new CEO either.
Now we hope for new catalysts:
- finalize an (top secret) agreement for the sglt2 inihbitor in animal health
- advance the anti-aging compounds to clinical study with potential pharma R&D partner (shouldn't it start in september?)
If I were Sirona, I would now communicate what the financing situation looks like.
In a german board someone wrote:
"I asked Christopher Hopton what the status of Sirona's funding was and the answer was that....
1) there is a financing plan for the 2023/2024 "Business Plan", which could include a "private placement".
2) it is possible to be put on a so-called "Presidential List" in order to be able to participate in this.
3) a "material non-dilutive funding event in 2023" is expected with a "very high probability".
Unfortunately, it reads as if nothing like this is expected for 2022.
Let's wait and see..."
if there is anyone who can still get information out of the shop, it would be nice if you could share it.